AZ/MSD’s PARP inhibitor shows promise as first-line ovarian cancer treatmentAstraZeneca and MSD’s Lynparza has scored its second Phase 3 win in the space of a week, this Share XAZ/MSD’s PARP inhibitor shows promise as first-line ovarian cancer treatmenthttps://pharmaphorum.com/news/az-msd-parp-inhibitor-ovarian-cancer/
MSD’s Keytruda plus chemo backed by NICE for lung cancerMerck & Co/MSD’s Keytruda can be provided via the Cancer Drugs Fund for first-line treatment of non-small cell Share XMSD’s Keytruda plus chemo backed by NICE for lung cancerhttps://pharmaphorum.com/news/msds-keytruda-plus-chemo-backed-by-nice-for-lung-cancer/
AZ/MSD’s Lynparza sees positive results in prostate cancerAstraZeneca and MSD have announced positive phase III results for their PARP inhibitor Lynparza (olaparib) in metastatic castration-resistant Share XAZ/MSD’s Lynparza sees positive results in prostate cancerhttps://pharmaphorum.com/news/az-msds-lynparza-sees-positive-results-in-prostate-cancer/
Merck claims a brace of head and neck cancer approvalsMerck & Co/MSD has done the double in head and neck cancer with a pair of FDA approvals Share XMerck claims a brace of head and neck cancer approvalshttps://pharmaphorum.com/news/merck-claims-a-brace-of-head-and-neck-cancer-approvals/
AZ and MSD’s Lynparza gets EU nod for hard-to-treat breast cancerThe European Commission has approved AstraZeneca and MSD’s Lynparza (olaparib) for the treatment of germline BRCA-mutated HER2-negative advanced Share XAZ and MSD’s Lynparza gets EU nod for hard-to-treat breast cancerhttps://pharmaphorum.com/news/az-and-msds-lynparza-gets-eu-nod-for-hard-to-treat-breast-cancer/
R&D round-up: Non-opioid painkiller space heats upAs the MHRA announced that it would be convening an Expert Working Group (EWG) to assess the risks Share XR&D round-up: Non-opioid painkiller space heats uphttps://pharmaphorum.com/views-and-analysis/rd-roundup-non-opioid-painkiller-space-heats-up/
Breaking new ground in digital content delivery for pharmaIt’s all too easy for pharmaceutical processes to slow marketing campaigns, rendering them unmanageable and ineffective, but a Share XBreaking new ground in digital content delivery for pharmahttps://pharmaphorum.com/sales-marketing/breaking-new-ground-in-digital-content-delivery-for-pharma/
Inspiring a new generation of women in pharmaAs part of a series of articles highlighting the role of women in the pharma industry, Richard Staines Share XInspiring a new generation of women in pharmahttps://pharmaphorum.com/views-and-analysis/inspiring-a-new-generation-of-women-in-pharma/
Keytruda cuts risk of death by 31% in esophageal cancer trialMSD’s Keytruda has cut the risk of death by 31% in patients with esophageal or esophagogastric junction carcinoma Share XKeytruda cuts risk of death by 31% in esophageal cancer trialhttps://pharmaphorum.com/news/keytruda-cuts-risk-of-death-by-31-in-esophageal-cancer-trial/
